Business
Perimeter Medical Imaging AI Closes C$3.6 Million Non-Brokered Private Placement
Perimeter Medical Imaging AI Closes C$3.6 Million Non-Brokered Private Placement Canada N...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\nPerimeter Medical Imaging AI Closes C$3.6 Million Non-Brokered Private Placement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\n\nLed by insiders, including Perimeter's CEO Adrian Mendes\nCapital to accelerate the commercialization of the current S-Series and strengthen the balance sheet through the pending FDA decision of Perimeter's upcoming B-Series, expected in the first half of 2026\nTORONTO and DALLAS, Dec. 9, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, today announced that it has closed a non-brokered private placement (the \"Offering\") of units of the Company (the \"Units\"). Pursuant to the Offering, the Company has issued an aggregate of 19,757,306 Units at a price of C$0.18 per Unit for aggregate gross proceeds of C$3,556,315. Each Unit is comprised of one common share in the capital of the Company (each a \"Common Share\") and one Common Share purchase Warrant (each a \"Warrant\"). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of C$0.35 for a period of 60 months.\n\"Commercialization of our current non-AI-enabled device, the S-Series, continues to gain traction as we expand our installed base at hospitals and consumable utilization increases among surgeons. We believe strategies that have already been implemented to seed the market with the S-Series will drive demand for the upcoming B-Series. Regarding the FDA PMA review process, we remain on track for a regulatory decision on our AI-powered B-Series in the first half of 2026 — an inflection point we believe will unlock significant opportunities for accelerated growth next year and beyond, as we now have many surgeons and hospitals eagerly awaiting the commercial availability of our AI-powered B-Series device. This private placement is an important milestone that strengthens our balance sheet through anticipated FDA decision in the first half of 2026, while supporting ...